Invest in Ionica Sciences, Inc.

A better way to test for Lyme disease

  • $61,500Amount raised
  • $1,000Minimum
  • $5,500,000Valuation cap

Purchased securities are not listed on any exchange. A secondary market for these securities does not currently exist and may never develop. You should not purchase these securities with the expectation that one eventually will.

Ionica Sciences, Inc. is offering securities under both Regulation D and Regulation CF through SI Securities, LLC ("SI Securities"). SI Securities is an affiliate of SeedInvest Technology, LLC, a registered broker-dealer, and member FINRA/SIPC. SI Securities will receive cash compensation equal to 7.50% of the value of the securities sold and equity compensation equal to 5.00% of the number of securities sold. Investments made under both Regulation D and Regulation CF involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest. Furthermore, this profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. Investors should review the risks and disclosures in the offering's draft. The contents of this profile are meant to be a summary of the information found in the company’s Form C. Before making an investment decision, investors should review the company’s Form C for a complete description of its business and offering information, a copy of which may be found both here and below.

Company Highlights

  • Current Investors include Global Lyme Alliance, the premier Lyme disease advocacy organization in the USA, LaunchNY and Center State Corporation for Economic Opportunity
  • Received 3 SBIR contracts from the Department of Defense and the Defense Health Agency. These non-dilutive awards reflect the capability and potential of Ionica's diagnostics platform
  • Filed an international patent application under the PCT (Patent Cooperation Treaty)
  • Completed pre-clinical study showing 91% clinical accuracy in identifying Lyme disease vs. the current diagnostic test accuracy of 57% (based on internal sensitivity testing of 23 samples, not yet verified by independent third parties, see data room for data sheet and research article dated 2016)
  • Ionica's Advisory Board includes Beckie Robertson, Managing Partner at Versant Ventures; Bill Rhodes, Retired President at BD Biosciences; Patricia DeLaMora, MD, Infectious Disease Specialist at Weill Cornell Medical Center

Fundraise Highlights

  • Total Amount Raised: US $61,500
  • Total Round Size: US $750,000
  • Raise Description:  Seed
  • Minimum Investment:  US $1,000 per investor
  • Security Type:  Crowd Note
  • Valuation Cap:  US $5,500,000
  • Offering Type:   Side by Side Offering

Focused on Lyme disease, Ionica's technology enables direct detection of Lyme disease through a simple blood test. 1.6x more accurate than today's test (see data room), the IonLyme(tm) Test will revolutionize the diagnosis and management of Lyme.

Lyme disease is the fastest growing vector borne disease in the United States. Though easily curable in its early stage, Lyme disease can be difficult to diagnose. The current laboratory tests to help in diagnosing Lyme are accurate only about 50% of the time in the early onset of infection. This poor "sensitivity" leads to thousands of missed diagnoses, allowing the disease to advance to often devastating effect. Once established, Lyme disease mimics the symptoms of many other diseases, further complicating diagnosis. It is extremely difficult to treat at its more advanced stage, when it has spread through the body. 

What's the problem with today's laboratory tests? The current tests depend on detecting evidence of your body's immune system fighting Lyme disease: antibodies. But Lyme disease "hides" from the immune system while it first establishes itself. With early, vague "flu-like" symptoms, your body might not yet have generated antibodies. This leads to "false negative" test results up to 50% of the time.

The IonLyme(tm) Test is different. The IonLyme Test detects a special protein (Outer surface protein A, "OspA") shed into the blood by the bacteria that causes Lyme disease. Other technologies are not sensitive enough to detect this protein with a simple lab test. Our breakthrough led the experts at the Global Lyme Alliance to invest in Ionica, to help bring this improved test to market. 

We hope to bring the IonLyme Test to market with our own laboratory in 2021. Ionica's sales team plan to establish IonLyme first with infectious disease experts who act as "key opinion leaders" for Lyme diagnosis and management. We will educate the millions of consumers and thousands of physicians with the help of the Global Lyme Alliance, our investor and partner. Lastly, insurance companies, to create coverage policies for IonLyme.

Pitch Deck

Media Mentions

The Team

Founders and Officers

Omar is CEO, also leading the development of our technology as it relates to materials and spectroscopy.   Co-Founding with Joel Tabb, PhD, Omar was inspired to improve Lyme disease diagnostics when a softball teammate had his life upended in the prime of life by a missed diagnosis, which led to a debilitating battle with Lyme disease

Omar Green, PhD


Omar is CEO, also leading the development of our technology as it relates to materials and spectroscopy.   Co-Founding with Joel Tabb, PhD, Omar was inspired to improve Lyme disease diagnostics when a softball teammate had his life upended in the prime of life by a missed diagnosis, which led to a debilitating battle with Lyme disease

Joel is a co-founder and also runs the development of our technology relating to biology.   Joel and Co-Founder Omar Green, PhD, were work colleagues at Agave Biosystems.  Their complementary scientific backgrounds led to the idea to combine aptamers and surface enhanced Raman scattering to create a new class of sensitive diagnostics

Joel Tabb, PhD


Joel is a co-founder and also runs the development of our technology relating to biology.   Joel and Co-Founder Omar Green, PhD, were work colleagues at Agave Biosystems.  Their complementary scientific backgrounds led to the idea to combine aptamers and surface enhanced Raman scattering to create a new class of sensitive diagnostics

Dean Koch

Chief Business Officer

Dean is an experienced life sciences executive, with a track record of successfully commercializing new diagnostic tests.  

Dean Koch

Chief Business Officer

Dean is an experienced life sciences executive, with a track record of successfully commercializing new diagnostic tests.  

Term Sheet

A Side by Side offering refers to a deal that is raising capital under two offering types. If you plan on investing less than US $20,000.00, you will automatically invest under the Regulation CF offering type. If you invest more than US $20,000.00, you must be an accredited investor and invest under the Regulation D offering type.

Fundraising Description

  • Round type:

  • Round size:
    US $750,000

  • Raised to date:
    US $61,500
    US $61,500 (under Reg CF only)

  • Minimum investment:
    US $1,000

  • Target Minimum:
    US $400,000
  • Key Terms

  • Security Type:
    Crowd Note

  • Conversion discount:

  • Valuation Cap:
    US $5,500,000

  • Interest rate:

  • Note term:
    24 months
  • Additional Terms

  • Custody of Shares

    Investors who invest $50,000 or less will have their securities held in trust with a Custodian that will serve as a single shareholder of record. These investors will be subject to the Custodian’s Account Agreement, including the electronic delivery of all required information.

  • Closing conditions:
    While Ionica Sciences, Inc. has set an overall target minimum of US $400,000 for the round, Ionica Sciences, Inc. must raise at least US $25,000 of that amount through the Regulation CF portion of their raise before being able to conduct a close on any investments below $20,000. For further information please refer to Ionica Sciences, Inc.'s Form C.

  • Transfer restrictions:
    Securities issued through Regulation CF have a one year restriction on transfer from the date of purchase (except to certain qualified parties as specified under Section 4(a)(6) of the Securities Act of 1933), after which they become freely transferable. While securities issued through Regulation D are similarly considered "restricted securities" and investors must hold their securities indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is available.

  • Use of Proceeds

    Investor Perks

    For those who invest $10,000:  A Free IonLyme Test coupon.  Quarterly investor update.  “Hydro Flask” with the  IonLyme Test logo.  Annual "Update with the CEO" group call.

    $25,000: All the above plus 5 IonLyme Test coupons.  IonLyme polo shirt.  Yearly group video chat session with CEO. 

    $50,000: All the above plus 10 IonLyme Test coupons. Yearly one-on-one video chat session with CEO. 

    $100,000 or more: All the above plus participation in quarterly group investor calls with management.  Private tour of IonLyme Test laboratory followed by dinner with Ionica leadership.

    It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.

    Prior Rounds

    The graph below illustrates the valuation cap or the pre-money valuation of Ionica Sciences, Inc.'s prior rounds by year.

    This chart does not represent guarantees of future valuation growth and/or declines.


  • Round Size
    US $225,000
  • Closed Date
    Aug 1, 2018
  • Security Type
    Convertible Note
  • Valuation Cap
    US $3,750,000
  • Pre-Seed

  • Round Size
    US $178,000
  • Closed Date
    Dec 31, 2016
  • Security Type
    SAFE Note
  • Valuation Cap
    US $1,186,667
  • Market Landscape

    In the US, physicians order 3.5 million Lyme disease tests annually, at approximately $200 each. Physicians know that poor performance of these tests requires them to interpret results with caution. The IonLyme Test price point is $400, so the US total market opportunity is $1.4 billion. We also estimate an international market of $600 million, but prioritize this below the US market.

    Approximately 70% of Lyme disease tests are performed in the large, commercial clinical laboratories, such as LabCorp and Quest. Today's test (which requires multiple steps) is typically billed to the insurance company or patient at $200.

    There are a few small, specialty laboratories, such as IgeneX, that market enhanced Lyme disease testing "panels" or test series. Their costs can exceed $700, and while marginally more accurate than the Lyme disease test Quest or LabCorp performs, it is still a test for antibodies, with poor clinical sensitivity.

    The IonLyme Test will be positioned as what we believe to be the only DIRECT Lyme disease test. Today's test is for Lyme specific antibodies. This only tells you that you've been exposed to the virus sometime in the last decade! Not that clinically useful). The IonLyme Test is different. It detects a protein (OspA) shed from the B. Burgdorferi bacteria that causes Lyme disease.

    Our early commercial efforts will educate patients, physicians and infectious disease specialists, focusing on Northeast and Upper Midwest. The IonLyme Test will be offered only through our laboratory at first (plan to meet clinical laboratory standards (CLIA)).

    We will have a small direct sales and marketing team, and collaborate with our investor/partner Global Lyme Alliance, to maximize impact.

    The IonLyme Test will be based on quality science, including prospective clinical studies. This drives adoption into practice and broad insurance coverage.

    Risks and Disclosures

    The development and commercialization of the Company’s products and services are highly competitive. It faces competition with respect to any products and services that it may seek to develop or commercialize in the future. Its competitors include major companies worldwide. The HealthTech market is an emerging industry where new competitors are entering the market frequently. Many of the Company’s competitors have significantly greater financial, technical and human resources and may have superior expertise in research and development and marketing approved services and thus may be better equipped than the Company to develop and commercialize services. These competitors also compete with the Company in recruiting and retaining qualified personnel and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, the Company’s competitors may commercialize products more rapidly or effectively than the Company is able to, which would adversely affect its competitive position, the likelihood that its services will achieve initial market acceptance and its ability to generate meaningful additional revenues from its products and services.

    The Company’s expenses will significantly increase as they seek to execute their current business model. Although the Company estimates that it has enough runway until end of year, they will be ramping up cash burn to promote revenue growth, further develop R&D, and fund other Company operations after the raise. Doing so could require significant effort and expense or may not be feasible.

    The Company projects aggressive growth in 2022. If these assumptions are wrong and the projections regarding market penetration are too aggressive, then the financial forecast may overstate the Company's overall viability. In addition, the forward-looking statements are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

    The Company has not prepared any audited financial statements. Therefore, investors have no audited financial information regarding the Company’s capitalization or assets or liabilities on which to make investment decisions. If investors feel the information provided is insufficient, then they should not invest in the Company.

    The outbreak of the novel coronavirus, COVID-19, has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The coronavirus pandemic and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the novel coronavirus. Nevertheless, the novel coronavirus presents material uncertainty and risk with respect to the Funds, their performance, and their financial results.

    The Company is pre-revenue and may not be successful in its efforts to grow and monetize its product. It has limited operating capital and for the foreseeable future will be dependent upon its ability to finance operations from the sale of equity or other financing alternatives. There can be no assurance that the Company will be able to successfully raise operating capital. The failure to successfully raise operating capital, and the failure to effectively monetize its products, could result in bankruptcy or other event which would have a material adverse effect on the Company and the value of its shares. The Company has limited assets and financial resources, so such adverse event could put investors’ dollars at significant risk.

    The Company conducts business in a heavily regulated industry and if it fails to comply with these laws and government regulations, it could incur penalties or be required to make significant changes to its operations or experience adverse publicity, which could have a material adverse effect on its business, financial condition, and results of operations. The healthcare and medical tech industries are heavily regulated and closely scrutinized by federal, state, and local governments. Comprehensive statutes and regulations govern the manner in which the Company provides and bills for services and collects reimbursement from governmental programs and private payors, contractual relationships with Providers, vendors and Clients, marketing activities, and other aspects of its operations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of the Company’s business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status, and exclusion from Medicare and Medicaid programs. The risk of the Company being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. The Company’s failure to accurately anticipate the application of these laws and regulations to the business or any other failure to comply with regulatory requirements could create liability and negatively affect the business. Any action against the Company for violation of these laws or regulations, even if they successfully defend against it, could cause them to incur significant legal expenses, divert management's attention from the operation of the business, and result in adverse publicity.

    The Company is still testing an early version of its product. Sophisticated technology products often contain errors or defects, such as errors in hardware, computer code, or other systems, particularly when first introduced or when new versions or enhancements are released. The development of new or enhanced products is a complex and uncertain process requiring the accurate anticipation of technological and market trends, as well as precise technological execution. Despite quality assurance measures, internal testing, and beta testing by customers, the Company cannot guarantee that its current and future products, including upgrades to those products, will be free of serious defects, which could result in lost revenue, refunds without a commensurate decrease in costs, delays in market acceptance, increase in costs, reputational harm, and costs associated with defending or settling claims. If upgrades are not properly implemented, the availability and functioning of its products could be impaired. 

    The Company has not filed a Form D for its prior offerings. The SEC rules require a Form D to be filed by companies within 15 days after the first sale of securities in the offering relying on Regulation D. Failing to register with the SEC or get an exemption may lead to fines, the right of investors to get their investments back, and even criminal charges. There is a risk that a late penalty could apply.

    Quality management plays an essential role in meeting customer requirements, preventing defects, improving the Company’s products and services, and maintaining the integrity of the safety and efficacy of its products. The Company's future success depends on their ability to maintain and continuously improve their quality management program. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in the Company or the Company's current or future products, which may result in the loss of sales and difficulty in successfully launching new products. In addition, a successful claim brought against the Company in excess of available insurance or not covered by indemnification agreements, or any claim that results in significant adverse publicity against the Company could have an adverse effect on their business and their reputation.

    The reviewing CPA has included a “going concern” note in the reviewed financials. The accompanying financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the recoverability of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses from inception of approximately $439,617 which, among other factors, raises substantial doubt about the Company's ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon management's plans to raise additional capital from the issuance of debt or the sale of stock, its ability to commence profitable sales of its flagship product, and its ability to generate positive operational cash flow. The accompanying financial statements do not include any adjustments that might be required should the Company be unable to continue as a going concern.

    The Company has engaged in related party transactions. Prior to 2018, an officer and shareholder of the Company advanced funds for operations in the amount of $22,610. These advances are non‐interest bearing and have no maturity dates. At December 31, 2019 and 2018, the amount of advances outstanding is $22,610 and are recorded under ‘Advances – related party’ on the balance sheets. This advance was subsequently forgiven by the officer and written off by the Company in 2020 in full. See Note 1 in Reviewed Financials. A related party receivable for advances to shareholders in the amount of $9,184 was forgiven and written off as during 2018. Amounts owed to the Company were non‐interest bearing and had no maturity date. The related party advance was expensed to ‘General and administrative’ expenses on the statement of operations for the year ended December 31, 2018. There were no similar advances during the year ended December 31, 2019.

    General Risks and Disclosures

    Start-up investing is risky. Investing in startups is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the company which can be found in this company profile and the documents in the data room below.

    Your shares are not easily transferable. You should not plan on being able to readily transfer and/or resell your security. Currently there is no market or liquidity for these shares and the company does not have any plans to list these shares on an exchange or other secondary market. At some point the company may choose to do so, but until then you should plan to hold your investment for a significant period of time before a "liquidation event" occurs. A "liquidation event" is when the company either lists their shares on an exchange, is acquired, or goes bankrupt.

    The Company may not pay dividends for the foreseeable future. Unless otherwise specified in the offering documents and subject to state law, you are not entitled to receive any dividends on your interest in the Company. Accordingly, any potential investor who anticipates the need for current dividends or income from an investment should not purchase any of the securities offered on the Site.

    Valuation and capitalization. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. In addition, there may be additional classes of equity with rights that are superior to the class of equity being sold.

    You may only receive limited disclosure. While the company must disclose certain information, since the company is at an early-stage they may only be able to provide limited information about its business plan and operations because it does not have fully developed operations or a long history. The company may also only obligated to file information periodically regarding its business, including financial statements. A publicly listed company, in contrast, is required to file annual and quarterly reports and promptly disclose certain events — through continuing disclosure that you can use to evaluate the status of your investment.

    Investment in personnel. An early-stage investment is also an investment in the entrepreneur or management of the company. Being able to execute on the business plan is often an important factor in whether the business is viable and successful. You should be aware that a portion of your investment may fund the compensation of the company's employees, including its management. You should carefully review any disclosure regarding the company's use of proceeds.

    Possibility of fraud. In light of the relative ease with which early-stage companies can raise funds, it may be the case that certain opportunities turn out to be money-losing fraudulent schemes. As with other investments, there is no guarantee that investments will be immune from fraud.

    Lack of professional guidance. Many successful companies partially attribute their early success to the guidance of professional early-stage investors (e.g., angel investors and venture capital firms). These investors often negotiate for seats on the company's board of directors and play an important role through their resources, contacts and experience in assisting early-stage companies in executing on their business plans. An early-stage company may not have the benefit of such professional investors.

    Representatives of SI Securities, LLC are affiliated with SI Advisors, LLC ("SI Advisors") Representatives of SI Securities, LLC are affiliated with SI Advisors, LLC ("SI Advisors"). SI Advisors is an exempt investment advisor that acts as the General Partner of SI Selections Fund I, L.P. ("SI Selections Fund"). SI Selections Fund is an early stage venture capital fund owned by third-party investors. From time to time, SI Selections Fund may invest in offerings made available on the SeedInvest platform, including this offering. Investments made by SI Selections Fund may be counted towards the total funds raised necessary to reach the minimum funding target as disclosed in the applicable offering materials.

    Ionica Sciences, Inc.'s Form C

    The Form C is a document the company must file with the Securities and Exchange Commission, which includes basic information about the company and its offering and is a condition to making a Reg CF offering available to investors. It is important to note that the SEC does not review the Form C, and therefore is not recommending and/or approving any of the securities being offered.

    Download Ionica Sciences, Inc.'s  Form C

    Frequently Asked Questions

    About Side by Side Offerings
    What is Side by Side?

    A Side by Side offering refers to a deal that is raising capital under two offering types. This Side by Side offering is raising under Regulation CF and Rule 506(c) of Regulation D.

    What is a Form C?

    The Form C is a document the company must file with the Securities and Exchange Commission (“SEC”) which includes basic information about the company and its offering and is a condition to making a Reg CF offering available to investors. It is important to note that the SEC does not review the Form C, and therefore is not recommending and/or approving any of the securities being offered.

    Before making any investment decision, it is highly recommended that prospective investors review the Form C filed with the SEC (included in the company's profile) before making any investment decision.

    What is Rule 506(c) under Regulation D?

    Rule 506(c) under Regulation D is a type of offering with no limits on how much a company may raise. The company may generally solicit their offering, but the company must verify each investor’s status as an accredited investor prior to closing and accepting funds. To learn more about Rule 506(c) under Regulation D and other offering types check out our blog and academy.

    What is Reg CF?

    Title III of the JOBS Act outlines Reg CF, a type of offering allowing private companies to raise up to $1 million from all Americans. Prior capital raising options limited private companies to raising money only from accredited investors, historically the wealthiest ~2% of Americans. Like a Kickstarter campaign, Reg CF allows companies to raise funds online from their early adopters and the crowd. However, instead of providing investors a reward such as a t-shirt or a card, investors receive securities, typically equity, in the startups they back. To learn more about Reg CF and other offering types check out our blog and academy.

    Making an Investment in Ionica Sciences, Inc.
    How does investing work?

    When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Ionica Sciences, Inc.. Once Ionica Sciences, Inc. accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Ionica Sciences, Inc. in exchange for your securities. At that point, you will be a proud owner in Ionica Sciences, Inc..

    What will I need to complete my investment?

    To make an investment, you will need the following information readily available:

    1. Personal information such as your current address and phone number
    2. Employment and employer information
    3. Net worth and income information
    4. Social Security Number or passport
    5. ABA bank routing number and checking account number (typically found on a personal check or bank statement)

    If you are investing under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.

    How much can I invest?

    An investor is limited in the amount that he or she may invest in a Reg CF offering during any 12-month period:

    • If either the annual income or the net worth of the investor is less than $100,000, the investor is limited to the greater of $2,000 or 5% of the lesser of his or her annual income or net worth.
    • If the annual income and net worth of the investor are both greater than $100,000, the investor is limited to 10% of the lesser of his or her annual income or net worth, to a maximum of $100,000.

    Separately, Ionica Sciences, Inc. has set a minimum investment amount of US $1,000.

    Accredited investors investing $20,000 or over do not have investment limits.

    After My Investment
    What is my ongoing relationship with the Issuer?

    You are a partial owner of the company, you do own securities after all! But more importantly, companies which have raised money via Regulation CF must file information with the SEC and post it on their websites on an annual basis. Receiving regular company updates is important to keep shareholders educated and informed about the progress of the company and their investment. This annual report includes information similar to a company’s initial Reg CF filing and key information that a company will want to share with its investors to foster a dynamic and healthy relationship.

    In certain circumstances a company may terminate its ongoing reporting requirement if:

    1. The company becomes a fully-reporting registrant with the SEC
    2. The company has filed at least one annual report, but has no more than 300 shareholders of record
    3. The company has filed at least three annual reports, and has no more than $10 million in assets
    4. The company or another party purchases or repurchases all the securities sold in reliance on Section 4(a)(6)
    5. The company ceases to do business

    However, regardless of whether a company has terminated its ongoing reporting requirement per SEC rules, SeedInvest works with all companies on its platform to ensure that investors are provided quarterly updates. These quarterly reports will include information such as: (i) quarterly net sales, (ii) quarterly change in cash and cash on hand, (iii) material updates on the business, (iv) fundraising updates (any plans for next round, current round status, etc.), and (v) any notable press and news.

    How can I sell my securities in the future?

    Currently there is no market or liquidity for these securities. Right now Ionica Sciences, Inc. does not plan to list these securities on a national exchange or another secondary market. At some point Ionica Sciences, Inc. may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Ionica Sciences, Inc. either lists their securities on an exchange, is acquired, or goes bankrupt.

    How do I keep track of this investment?

    You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement. If invested under Regulation CF you may also receive periodic updates from the company about their business, in addition to monthly account statements.

    Other General Questions
    What is this page about?

    This is Ionica Sciences, Inc.'s fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity. If the company runs a side by side offering that includes an offering under Regulation CF, you may also find a copy of the Ionica Sciences, Inc.'s Form C. The Form C includes important details about Ionica Sciences, Inc.'s fundraise that you should review before investing.

    How can I (or the company) cancel my investment under Regulation CF?

    For offerings made under Regulation CF, you may cancel your investment at any time up to 48 hours before a closing occurs or an earlier date set by the company. You will be sent a reminder notification approximately five days before the closing or set date giving you an opportunity to cancel your investment if you had not already done so. Once a closing occurs, and if you have not canceled your investment, you will receive an email notifying you that your securities have been issued. If you have already funded your investment, your funds will be promptly refunded to you upon cancellation. To cancel your investment, you may go to your account's portfolio page by clicking your profile icon in the top right corner.

    What if I change my mind about investing?

    If you invest under any other offering type, you may cancel your investment at any time, for any reason until a closing occurs. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your account's portfolio page by clicking your profile icon in the top right corner.